Olfactory Cleft Obstruction and Electrophysiological Olfactory Bulb Generated Beta Field Potentials Predict Olfactory Restoration by Dupilumab in Patients with Chronic Rhinosinusitis with Nasal Polyps

What this Trial Is About

Researchers are studying patients with chronic rhinosinusitis with nasal polyps (CRSwNP) who experience smell loss. The study aims to find out whether blockage of the olfactory cleft and specific brain signals related to breathing and sniffing can predict the return of the sense of smell in patients treated with dupilumab. This is an observational study led by Northwestern University. Participants who have had prior sinus surgery for CRSwNP and continue to have smell loss will start dupilumab treatment at a standard dose of 300 mg every two weeks for 24 weeks. During this time, researchers will assess the degree of olfactory cleft obstruction and use electrophysiological tests to measure brain signals related to smell. Over six months of treatment, participants will be monitored for changes in their sense of smell using the Brief Smell Identification Test at 26 weeks. The study includes evaluations of olfactory cleft blockage and electrophysiological responses. Participants' smell function and related measurements will be tracked to understand factors predicting smell recovery while receiving dupilumab therapy.

Olfactory Cleft Obstruction and Electrophysiological Field Potentials Predict Olfactory Restoration by Dupilumab in CRSwNP Patients.